Dialyzable Leukocyte Extract (Transferon™)‎ Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit

Abstract EN

Immunomodulatory agents have been proposed as therapeutic candidates to improve outcomes in sepsis.

Transferon™, a dialyzable leukocyte extract (DLE), has been supported in Mexico as an immunomodulatory adjuvant in anti-infectious therapy.

Here we present a retrospective study describing the experience of a referral pediatric intensive care unit (PICU) with Transferon™ in sepsis.

We studied clinical and laboratory data from 123 patients with sepsis (15 in the DLE group and 108 in the control group) that were admitted to PICU during the period between January 2010 and December 2016.

Transferon™ DLE use was associated with lower C reactive protein (CRP), increase in total lymphocyte counts (TLC), and decrease in total neutrophil count (TNC) 72 hours after Transferon™ DLE administration.

The control group did not present any significant difference in CRP values and had lower TLC after 72 hours of admission.

There was no difference in PICU length of stay between control and Transferon™ DLE group.

Transferon™ DLE administration was associated with a higher survival rate at the end of PICU stay.

This study shows a possible immunomodulatory effect of Transferon™ on pediatric sepsis patients.